Ratings Supermax Corporation

Equities

SUPERMX

MYL7106OO007

End-of-day quote BURSA MALAYSIA Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
0.85 ^MYR	-1.16%		+6.25%	-9.57%

02:32pm	Supermax Corporation Berhad Announces Audit Committee Changes, Effective May 8, 2024	CI
02:32pm	Supermax Corporation Berhad Announces Re-Designation of Wong Phait Lee from Non Executive Director to Executive Director, Effective May 8, 2024	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company's share price in relation to its net book value makes it look relatively cheap.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company has insufficient levels of profitability.
With an expected P/E ratio at 85 and 45.95 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SUPERMAX CORPORATION	-9.57%	458M		C+
COLOPLAST A/S	+8.96%	26.92B		B+
SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED	-31.01%	3.12B		B-
WINNER MEDICAL CO., LTD.	-15.97%	2.52B		C+
INTCO MEDICAL TECHNOLOGY CO., LTD.	+18.11%	2.47B	-	A-
HARTALEGA HOLDINGS	+3.70%	2B		B
HARBIN FUERJIA TECHNOLOGY CO., LTD.	-9.47%	1.91B		-
TOP GLOVE CORPORATION BHD.	-2.22%	1.48B		B
NAKANISHI INC.	+2.24%	1.31B		-
KOSSAN RUBBER INDUSTRIES	+18.92%	1.18B		C

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes